vaccines

an Open Access Journal by MDPI

IMPACT
Indexed in: CITESCORE
FACTOR
7.8 PubMed 7.0

Academic Open Access Publishing

since 1996
 vaccines
an Open Access Journal by MDPI

Editor-in-Chief Message from the Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Vaccines (ISSN 2076-393X) has had a 11-year history of
publishing peer-reviewed state of the art research that
advances the knowledge of immunology in human disease
protection. Immunotherapeutics, prophylactic vaccines,
immunomodulators, adjuvants and the global differences
in regulatory affairs are some of the highlights of the
research published that have shaped global health. Our
open access policy allows all researchers and interested
parties to immediately scrutinize the rigorous evidence
our publications have to offer. We are proud to present
the work and perspectives of many to contribute to future
decisions concerning human health.

Author Benefits
Open Access Unlimited and free access for readers
No Copyright Constraints Retain copyright of your work and free use of
your article
Thorough Peer-Review
2022 Impact Factor: 7.8 (Journal Citation Reports - Clarivate, 2023)
Discounts on Article Processing Charges (APC) If you belong to an institute
that participates with the MDPI Institutional Open Access Program
No Space Constraints, No Extra Space or Color Charges No restriction on
the maximum length of the papers, number of figures or colors
Coverage by Leading Indexing Services Scopus, SCIE (Web of Science),
PubMed, PMC, Embase, CAPlus / SciFinder, and other databases
Rapid Publication A first decision is provided to authors approximately 17.6
days after submission; acceptance to publication is undertaken in 2.9 days
(median values for papers published in this journal in the first half of 2023)
 IMPACT
Indexed in: CITESCORE
FACTOR
7.8 PubMed 7.0

Aims and Scope Sections

Vaccines is an international, peer-reviewed open access Vaccines against Infectious

journal focused on laboratory and clinical vaccine research, Diseases
Therapeutic Vaccines and
utilization and immunization. It publishes reviews, research
Antibody Therapeutics
articles, case reports, etc. There is no restriction on the Cancer Vaccines and
maximum length of papers. We encourage scientists to Immunotherapy
publish the results in as much detail as possible. Influenza Virus Vaccines
HIV Vaccines
The scope of Vaccines includes: Veterinary Vaccines
Vaccines against (re)emerging
Immunology mechanisms and Tropical Infections Diseases
Animal models for immunologic diseases Epidemiology
Innate and Adaptive Immunity in
Viral immunology Vaccination
Vaccines and Society
Immunopathogenesis
Vaccine Adjuvants
Vaccine developmentand efficacy evaluation Attenuated/Inactivated/Live and
Vectored Vaccines
Immune responses to vaccines Clinical Immunology

Vaccine technology Cellular/Molecular Immunology

Pathogens-host Immune
Vaccine vectors, adjuvants and immunomodulators Interface
Human Papillomavirus Vaccines
Prophylactic vaccines, therapeutic vaccines, AIDS
Hepatitis Virus Vaccines
vaccines, gene vaccines, vaccines in bioterrorism COVID-19 Vaccines and
Vaccination
Regulatory affairs, commercial utilization, safety
Vaccination Optimization
DNA and mRNA Vaccines
Vaccine Efficacy and Safety

Editorial Office
Vaccines Editorial Office
vaccines@mdpi.com
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland
Tel:  +41  61  683  77  34
www.mdpi.com
mdpi.com/journal/vaccines
MDPI is a member of

Follow

facebook.com/MDPIOpenAccessPublishing

twitter.com/MDPIOpenAccess

linkedin.com/company/mdpi

instagram.com/mdpiopenaccess

weibo.com/mdpicn

Wechat: MDPI-China

Subscribe
blog.mdpi.com

mdpi.com  mdpi.com/journal/vaccines
Visit mdpi.com for a full list of offices and contact information.
MDPI is a company registered in Basel, Switzerland, No. CH-270.3.014.334-3,
whose registered office is at St. Alban-Anlage 66, CH-4052 Basel, Switzerland.